Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.59 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19729987 | 1.00 | LRRK2 (0.78) | LRRK2CYP1A2TTK | |
| SCHEMBL19729876 | 1.00 | LRRK2 (0.78) | LRRK2CYP1A2TTK | |
| SCHEMBL19729865 | 0.90 | LRRK2 (0.79) | LRRK2CYP1A2 | |
| SCHEMBL19729977 | 0.90 | LRRK2 (0.79) | LRRK2CYP1A2 | |
| SCHEMBL19729995 | 0.90 | LRRK2 (0.79) | LRRK2CYP1A2 | |
| SCHEMBL19729976 | 0.90 | LRRK2 (0.77) | LRRK2CYP1A2 | |
| SCHEMBL19729862 | 0.90 | LRRK2 (0.77) | LRRK2CYP1A2 | |
| SCHEMBL19729986 | 0.90 | LRRK2 (0.77) | LRRK2CYP1A2 | |
| SCHEMBL19716123 | 0.88 | LRRK2 (1.00) | LRRK2CYP1A2 | |
| SCHEMBL19716105 | 0.88 | LRRK2 (1.00) | LRRK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834439-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834439-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11591316-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3472153-B1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11111235-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210002260-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9932325-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932325-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2017218843-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-20210002260-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-11591316-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-11834439-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-20180051009-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
| US-11111235-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885TTK 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.